Product Description
Erlotinib Hydrochloride 150mg Tablets: What the Published Guidance Says
Cytotoxic and targeted agents spanning the taxane, antifolate and EGFR-tyrosine-kinase-inhibitor classes, supplied with the analytical and stability documentation oncology procurement requires.
This page collects the supply-relevant facts for Erlotinib Hydrochloride 150mg Tablets — specification, testing, packaging and the registration paperwork that travels with the batch.
- EGFR tyrosine-kinase inhibitors and their toxicity profile In its review of non-small cell lung cancer, the WHO Expert Committee recorded that EGFR tyrosine-kinase inhibitors are generally well tolerated, with diarrhoea occurring in more than 60% of patients treated, characteristic dermatological toxicity and rash across the class, and potential hepatic toxicity. Rare but severe gastrointestinal toxicity, including perforation, was noted particularly with erlotinib. WHO EML Expert Committee — Non-small cell lung cancer review
- 2025 extended access to checkpoint inhibitors Pembrolizumab was added to the Model List as first-line monotherapy for metastatic cervical cancer, metastatic colorectal cancer and metastatic non-small cell lung cancer, with atezolizumab and cemiplimab as therapeutic alternatives for the lung indication. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
- WHO applies a hard benefit threshold to cancer listings When the September 2025 revision was prepared, WHO evaluated 25 cancer medicines across seven applications and states that only therapies proven to prolong life by at least four to six months are included on the Model List. Listing is therefore a deliberately narrow signal, not a catalogue of everything approved. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Erlotinib Hydrochloride 150mg Tablets. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.
Erlotinib Hydrochloride 150mg Tablets: Specification, Pack & Documentation Summary
| Product Name | Erlotinib Hydrochloride Tablets (Erlotinib 150mg Oral Tablets) |
| Specification | Each tablet contains: Erlotinib Hydrochloride equivalent to 150mg Erlotinib |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredient | Erlotinib (as Erlotinib Hydrochloride) |
| Pharmacological Class | Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (Targeted Therapy) |
| Route of Administration | Oral administration (swallowed whole with water; take at least 1 hour before or 2 hours after meals, on an empty stomach). Take at approximately the same time each day. |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | Oncology — Oncology |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Afatinib Dimaleate 40mg Tablets, Gefitinib Tablets 250mg, Sunitinib Malate 12.5mg Capsules, Pemetrexed Disodium Injection 100mg, Paclitaxel Albumin-Bound 100mg/20mL.
How Erlotinib Hydrochloride 150mg Tablets Is Tested and Released
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Every batch of Erlotinib Hydrochloride 150mg Tablets is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
Release testing on this presentation is built around:
- Testing for related substances and impurities
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
How Erlotinib Hydrochloride 150mg Tablets Is Packed, Labelled and Shipped
- Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
- Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.
Regulatory Support for Erlotinib Hydrochloride 150mg Tablets
Documents for Erlotinib Hydrochloride 150mg Tablets are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.
- Method validation, stability protocol and the shelf-life justification for the marketed pack.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
The context for Erlotinib Hydrochloride 150mg Tablets is its place among cancer medicines reviewed for the WHO Model List. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.
Questions We Are Asked About Erlotinib Hydrochloride 150mg Tablets
What pack size is available for Erlotinib Hydrochloride 150mg Tablets?
This presentation is normally supplied as Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Where your market requires a different count, bottle or carton, we quote to your artwork and extend the stability file to the new pack.
What documentation comes with a shipment of Erlotinib Hydrochloride 150mg Tablets?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Erlotinib Hydrochloride 150mg Tablets support a registration filing?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
What documentation comes with an oncology order?
Batch COA including the full impurity profile and sterility results, stability data, DMF and dossier packages, plus registration support documents.
Why do you publish the WHO toxicity notes?
Because they are part of how this class is used safely. Paclitaxel hypersensitivity and EGFR-inhibitor rash are real clinical facts that procurement and clinical teams should both see on the same page.
Companion Products — Oncology
- Afatinib Dimaleate 40mg Tablets — 40mg
- Gefitinib Tablets 250mg — 250mg
- Sunitinib Malate 12.5mg Capsules — 12.5mg
- Pemetrexed Disodium Injection 100mg — 100mg
- Paclitaxel Albumin-Bound 100mg/20mL — 100mg
Browse the full Oncology range; all Tablets; the complete product catalogue.
Request a Quotation for Erlotinib Hydrochloride 150mg Tablets
For tenders and programme supply, send the line item, pack size, quantity and destination for Erlotinib Hydrochloride 150mg Tablets 150mg. We return a quotation with lead time, documentation list and sample availability in one response.
Sources & Regulatory Notes
- WHO EML Expert Committee — Non-small cell lung cancer review
- WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
